Oral Administration of Semicarbazide Limits Weight Gain together with Inhibition of Fat Deposition and of Primary Amine Oxidase Activity in Adipose Tissue by Mercader, Josep et al.
Hindawi Publishing Corporation
Journal of Obesity
Volume 2011, Article ID 475786, 10 pages
doi:10.1155/2011/475786
Research Article
Oral Administration of SemicarbazideLimits WeightGain
together with Inhibition of Fat Deposition and of Primary Amine
Oxidase Activity in Adipose Tissue
Josep Mercader,1,2 Zsuzsa Ifﬁ´ u-Solt´ esz,1,2 SandyBour,2 andChristianCarp´ en´ e1,2
1Institut National de la Sant´ ee td el aR e c h e r c h eM ´ edicale, INSERM U1048, Equipe 3, 12MC, IFR 150,
Bat. L4, CHU Rangueil, BP 84225, 31432 Toulouse Cedex 4, France
2Universit´ e Paul Sabatier, 12MC, Centre Hospitalier Universitaire de Rangueil, 31432 Toulouse, France
Correspondence should be addressed to Christian Carp´ en´ e, christian.carpene@inserm.fr
Received 28 June 2010; Accepted 22 December 2010
Academic Editor: A. Halpern
Copyright © 2011 Josep Mercader et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
An enzyme hitherto named semicarbazide-sensitive amine oxidase (SSAO), involved in the oxidation of primary amines, is
abundantly expressed in adipocytes. Although SSAO physiological functions remain unclear, several molecules inhibiting its
activity have been described to limit fat accumulation in preadipocyte cultures or to reduce body weight gain in obese rodents.
Here, we studied whether oral administration of semicarbazide, a prototypical SSAO inhibitor, limits fat deposition in mice.
Prolonged treatment with semicarbazide at 0.125% in drinking water limited food and water consumption, hampered weight
gain, and deeply impaired fat deposition. The adiposomatic index was reduced by 31%, while body mass was reduced by 15%.
Such treatment completely inhibited SSAO, but did not alter MAO activity in white adipose tissue. Consequently, the insulin-
like action of the SSAO substrate benzylamine on glucose transport was abolished in adipocytes from semicarbazide-drinking
mice, while their insulin sensitivity was not altered. Although semicarbazide is currently considered as a food contaminant with
deleterious eﬀects, the SSAO inhibition it induces appears as a novel concept to modulate adipose tissue development, which is
promising for antiobesity drug discovery.
1.Introduction
Pharmacological agents known to inhibit a membrane
enzyme involved in the oxidation of various primary
amines, and hitherto named semicarbazide-sensitive amine
oxidase (SSAO, E.C. 1.4.3.6, pending novel classiﬁcation E.C.
1.3.4.21) have been reported to limit body weight gain in
diverse animal models. Most of these observations of such
“slimming eﬀect” with the tested agents were not expected
since they were evidenced in studies initially focused on
vascular pharmacology. The ﬁrst reported observation was
made by Yu and coworkers in the obese and diabetic
KKAy mice [1]. Whilst the authors aimed to demonstrate
an antiatherogenic eﬀect of (E)-2-(4-ﬂuorophenethyl)-3-
ﬂuoroallylamine (FPFA), they observed that this compound
r e d u c e dw e i g h tg a i ni no b e s eK K A ym i c ef e da na t h e r o g e n i c
diet. In the same report, Yu and colleagues demonstrated
that FPFA was able to inhibit both SSAO and monoamine
oxidases (MAO). More recently, by performing pharmaco-
logical research on arterial thickness alteration, Mercier and
colleaguesrepeatedlyadministratedthereferenceinhibitorof
SSAO,namely,semicarbazide,at100mg/kgbw/dtoSprague-
Dawley [2], and Brown-Norway rats [3]. In both models,
the authors observed a dramatically reduced body weight
gain in response to the SSAO inhibitor, which also induced
a decrease in the pressure resistance of arteries, as initially
expected.
We have also reported that aminoguanidine, which
inhibits SSAO[4]togetherwithnitric oxide synthases(NOS)
and diamine oxidase (DAO) [5], was able to limit WAT
extension without notably altering calorie intake and body
weight gain in obese Zucker rats [6]. Then, we observed
that the combined inhibition of SSAO and MAO, obtained
by repeated injections of semicarbazide plus pargyline, or2 Journal of Obesity
by daily i.p. administration of phenelzine (an antidepressant
which inhibits both MAO and SSAO), produced concomi-
tant limitation of body weight gain in the obese Zucker
rat [7, 8]. Therefore, at least four distinct pharmacological
agents tested in vivo to inhibit SSAO were able to alter energy
balance and to lower body weight gain in rodents.
SSAO is historically known for its presence in vessels
[9]: in endothelial cells, where it is known as SSAO/VAP-
1 owing to its vascular adhesion properties [10] and in
smooth muscle cells, where it is involved together with
another copper-containing amine oxidase, the lysyl oxidase,
in extracellular matrix maturation [2, 11]. In fact, SSAO
is also highly expressed in white adipose tissue (WAT)
[12]. Tissue-distribution studies have recently evidenced
that the SSAO amount in adipocytes is extremely elevated,
regarding gene expression [13], protein abundance [14],
or activity level [6], including in man [15]. With an
approach aiming at unravelling the role for such SSAO
abundance at the surface of fat cells [15], we observed in
vitro that exogenous amines exert insulin mimicry when
added to adipocyte preparations. Actually, at submillimolar
concentrations, benzylamine elicits, in a SSAO-dependent
manner, an activation of glucose transport and an inhibition
of lipolysis in isolated fat cells, from human [15]o rr o d e n t
origin [16]. In addition, benzylamine [17], methylamine
[18], or other SSAO substrates [19], activate adipocyte
diﬀerentiation in several preadipocyte lineages and therefore
partly reproduce the adipogenic action of insulin. Lastly,
in vitro experiments showed that the hydrazine derivative
phenelzine (which inhibits SSAO) alters the adipocyte dif-
ferentiation of cultured human and mouse preadipocytes
[20]. We therefore hypothesized that endogenous or dietary
amines may reproduce in vivo such anabolic insulin-like
eﬀects, and if the amines can reach WAT, any sustained
pharmacological inhibition of their oxidation could hamper
fat deposition. In this context, it appeared essential to verify
whether inhibition of fat mass extension was an important
issue occurring during the body weight gain reduction
induced by the above-mentioned agents, all of them sharing
the property to inhibit SSAO.
This prompted us to further test whether the per os
administration of the prototypical SSAO inhibitor, semicar-
bazide, was limiting fat deposition. The following results
show that, when given in the drinking water, semicarbazide
not only inhibited the SSAO activity in WAT, but also
limited food consumption, and to a larger extent, hampered
fat accretion in both visceral and subcutaneous fat depots.
Moreover, the prevention of body weight gain observed
during oral administration of semicarbazide was not accom-
panied by any worsening of the plasma levels of metabolites
or oxidative stress markers. Finally, since semicarbazide oral
toxicity has been recently suspected [21–23], the need for
further investigations of the putative antiobesity eﬀects of
other SSAO inhibitors is discussed.
2.MaterialsandMethods
2.1. Animals and Treatments. FVB/n male mice (Charles
River, l’Arbresle, France) were separated in two groups of
8 mice with equivalent body weight at the age of 5 weeks.
They were housed at 2 animals per cage with unlimited
access to standard rodent chow (Global rodent diet, Harlan,
France) and water (control), or to a semicarbazide solu-
tion(semicarbazide-drinking).Semicarbazidehydrochloride
(Sigma-Aldrich, Saint Quentin Fallavier, France) was dis-
solved in drinking water and given as a 0.125% solution
that was changed weekly. Body mass, food, and water
consumption were checked weekly, and at the end of an
8-week treatment period, the mice were sacriﬁced after
overnight fasting. Ten other 10-wk-old FVB/n mice grown
under standard conditions were used for tissue distribution
study of SSAO activity and preliminary lipolytic studies.
Housing conditions and experimental procedures followed
in the IFR 150 animal unit were in accordance with the
European Union regulations on the use of animals for
scientiﬁc research.
2.2. Tissue Sampling and In Vitro Functional Assays on
Adipocytes. Once obtained, plasma was immediately frozen
at −80◦C, and circulating metabolites (glucose, insulin,
triglycerides, fatty acids, etc.) were determined using a
Cobas-Mira + multi-analyser, according to the manufac-
turer’ instructions (Roche, Neuilly, France). Once weighed,
the perirenal, retroperitoneal, and epididymal white adi-
pose tissues were pooled (and named as visceral WAT),
immediately digested to obtain adipocyte preparations for
glucose uptake assays and lipolysis measurements, as pre-
viously described [8], or for cell size determination under
microscope using Lucia G software (Nikon). Portion of the
tissues were also frozen for further determinations of DNA
and protein contents and for amine oxidase assays. DNA
content was assessed in WAT after proteinase K digestion,
chloroform/ethanolextraction,and260/280nmspectropho-
tometric readings. Protein content was determined using DC
Protein Assay kit (BioRad, Hercules, CA).
2.3. In Vitro 2-Deoxyglucose Uptake Assay. Freshly isolated
adipocytes were diluted in around 10-fold their volume
of Krebs-Ringer containing 15mM sodium bicarbonate,
10mM HEPES, 2mM pyruvate, and 3.5% serum bovine
albumin. Then 400μL of cell suspension was distributed
into plastic incubation vials and incubated 45min at 37◦C
with the tested agents, just before 10min exposure to
0.1mM [3H]-2-deoxyglucose (2-DG). Separation between
extracellular and internalized hexose was performed on
200μL aliquots by centrifugation through dinonyl-phthalate
layer which allowed to separate buoyant intact fat cells
from medium, as previously described [6]. 2-DG uptake
was expressed as fold increase over basal uptake or even as
percentage of maximal response to insulin, with basal uptake
set at 1 or at 0%, respectively [8].
2.4. Amine Oxidase Activity. Oxidative deamination was
measured by extracting the oxidation products of 0.1mM
[14C]-benzylamine (from Amersham Biosciences, Bucking-
hamshire, UK) or 0.5mM [14C]-tyramine (from Sigma-
Aldrich, St Quentin Fallavier, France) after incubation for
30min in 200μL of 200mM phosphate buﬀer, pH 7.5, in theJournal of Obesity 3
presence of protease inhibitors and approx. 100μgp r o t e i n
of homogenates prepared just before assays from thawed
tissues, as previously described [24]. 15-min preincubation
with 1mM semicarbazide or 0.5mM pargyline was used
to selectively inhibit SSAO or MAO activity, respectively, as
previously reported [25].
2.5. Gene Expression Analysis. Real-time quantitative RT-
PCR was performed using oligonucleotide primers speciﬁc
for the indicated genes, designed with Primer Express
software (Perkin-Elmer Life Sciences, Courtaboeuf, F), and
the sequences of which are reported in [25], for MAO-
A, MAO-B, AOC2, and AOC3,o ri n[ 26] for adipokines,
or either given as supplemental data to [27]. Total RNAs
were extracted from mature adipocytes, using RNeasy
minikit, then reverse-transcribed using random hexamers
and Superscript II reverse transcriptase (Invitrogen, Cergy-
Pontoise, F). Reactions without reverse transcriptase (RT-)
were performed in parallel to estimate DNA contamination.
Real-time RT-PCR was performed using the primers in the
presence of 6.25ng cDNA and SYBR green Universal PCR
Mix (Eurogentec, Angers, F). Fluorescence was analysed in
an ABI PRISM 7500 Sequence Detection device (Taqman,
Applied Biosystems, Foster City, CA). Analysis of 18S RNA
was performed in parallel using the Ribosomal RNA Control
Taqman Assay Kit (Applied Biosystems) to normalize gene
expression as already reported [25, 26]. For each gene,
results were expressed as arbitrary units: 2(Ct18S-Ctgene) × (1 −
1/(2Ct RT-Ctgene)) × 106, where Ct corresponds to the number
of cycles reaching ﬂuorescence threshold.
2.6. Statistical Analysis. Data are given as means ± stan-
dard error of the mean (SEM). Comparisons between
semicarbazide-treated and control groups were determined
using an unpaired Student’s t-test.
3. Results
3.1. Tissue Distribution of SSAO Activity in Mice. Table 1
shows that the SSAO activity was higher in adipose depots
than in any other studied organ. As previously reported [28],
the oxidation of the prototypic SSAO substrate benzylamine
was inhibited by semicarbazide in all the homogenates.
However, the visceral WAT of FVB/n mouse was richer
in SSAO activity than the subcutaneous WAT and than
the interscapular brown fat. Aorta, duodenum, and kidney
exhibited a lower capacity to oxidize benzylamine than the
adipose depots.
3.2. Changes in Body Weight and Adiposity in Semicarbazide-
Drinking Mice. FVB/n mice exhibits a rapid growth after
weaning, which accounts for a week increase of about
10% of their body mass. We have therefore tested whether
semicarbazide oral treatment could hamper adipose tissue
development during such period of intense anabolism
and substantial fattening. To this aim, semicarbazide was
administered at 125mg/100mL in the drinking water of 5-
week-old mice. Since changes in body mass and in water
Table 1: Tissue distribution of semicarbazide-sensitive amine oxi-
dase activity in control mice.
Tissue
Semicarbazide-inhibited oxidation
of 0.1mM benzylamine
(nmoles/mg protein/min)
Visceral WAT 4.402 ± 0.368 (8)
Subcutaneous WAT 2.250 ± 0.144 (4)
Interscapular brown
fat 0.860 ± 0.027 (4)
Aorta 0.506 ± 0.064 (10)
Duodenum 0.201 ± 0.018 (4)
Kidney 0.018 ± 0.005 (10)
Homogenates were preincubated for 15min without or with 1mM semi-
carbazide before a 30-minute incubation in the presence of 0.1mM [14C]-
benzylamine. The semicarbazide-inhibited oxidation is representative of the
SSAO activity. Mean ± SEM of the number of determinations indicated in
parentheses. Analysis of variance showed that the factor tissue was highly
inﬂuencing SSAO activity (P<10−18).
consumption occurred between the beginning and the end
of the 8-week treatment, the ingestion of such dose of semi-
carbazide was calculated to reach a mean daily intake com-
prised between 123 and 150mg/kg/day (equivalent to 1100–
1350μmol/kg/d). This range is similar to the dose used in
toxicology studies showing no signs of any distress [29]a n d
islowerthantheoralLD50 statedinmouse(225mg/kg,avail-
able at http://www.carl-roth.de/jsp/en-de/sdpdf/4681e.pdf).
The semicarbazide oral administration clearly limited the
growth of young mice. An immediate decline was detected
in the growth curve after the ﬁrst week of treatment, while
retardationpersistedthroughoutthetreatment(Figure 1).At
the end of the treatment, the semicarbazide-drinking mice
weighed 15% less than their control, since body weights were
24.7 ± 0.6 and 29.1 ± 0.6g, respectively (n = 8, P<. 001).
The subsequent lowered body weight gain found after 8
weeks of semicarbazide ingestion (2.4 ± 0.5g) represented
only one third of that observed in the control group (6.9 ±
0.7g, n = 8, P<. 001). It was concomitant with a signiﬁcant
reduction in the cumulative water and food consumption,
observed during the same period (equivalent to a 29% and
12% reduction, resp., not shown).
A clear reduction of adiposity was found in the
semicarbazide-drinking mice, at least when comparing the
mass of the epididymal, perirenal, retroperitoneal, and
inguinal fat pads (Figure 2). Since the body weight was lower
in the semicarbazide-treated mice, it was more convenient
to compare the adiposomatic index between the two groups,
that is, the percentage of the sum of dissected fat depots
relative to body weight [8]. This index fell from 5.8 ± 0.3%
to 4.0 ± 0.3% (n = 8, P<. 001), corresponding to a
31% reduction. The mass of the interscapular brown fat pad
was also reduced by approximately 20% in semicarbazide-
drinking mice: 82 ±4 versus103 ±6mgincontrol(P<. 01).
T w oa p p r o a c h e sw e r ep e r f o r m e dt of u r t h e re x a m i n et h e
limitation of WAT development. First, the determination
of adipocyte diameter distribution clearly showed a fall in
the proportion of the larger adipocytes, together with an4 Journal of Obesity
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Figure 1: Body weight changes in mice treated or not with
orally administered semicarbazide. Two groups of age- and weight-
matched mice were constituted after weaning and before oral
administration of semicarbazide (week 0), given at 125mg/100mL
in drinking solution (semidrinking, open triangles), while control
(black symbols) had free access to tap water. Mean ± SEM of 8
determinations. Diﬀerent from corresponding control at ∗P<. 05,
∗∗P<. 01, ∗∗∗P<. 001.
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Figure 2: Eﬀect of chronic semicarbazide ingestion on adipose
tissue mass in male mice. Mean ± S E Mo f8d e t e r m i n a t i o n so f
epididymal (EPIWAT), perirenal + retroperitoneal (PERWAT), or
inguinal (SCWAT) fad pad weights. Diﬀerent from corresponding
control (black columns) at ∗∗P<. 01, ∗∗∗P<. 001.
increase in the proportion of small fat cells (Figure 3(a)).
This resulted in a signiﬁcant decrease of the mean fat cell
size (Figure 3(b)), reﬂecting an impaired lipid accumulation
inside the fat cells. Second, the DNA content per 100mg
tissue was greater in WAT from semicarbazide-drinking mice
than in control, indicating that more numerous and smaller
cells were present per unit of tissue mass in the treated
than in the control animals, the fat depots of which con-
tained larger, heavier, lipid-laden adipocytes (Figure 3(c)).
These two approaches, together with the lack of increased
adipogenic markers (see below), indicated that the WAT of
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Figure 3: Eﬀect of chronic semicarbazide ingestion on the
cellularity of visceral adipose tissues. Adipocytes isolated from
visceral adipose tissues were subjected to size analysis and counted
according to the indicated distribution of cell diameter classes
(a). Mean fat cell diameter was calculated (b) while DNA was
extracted from pieces of visceral WAT and determined as described
in Section 2 (c). Mean ± SEM of six mice per group. Diﬀerent from
control at ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001.
semicarbazide-drinking mice partially escaped to the age-
dependent lipid accumulation and contained adipocytes
having a reduced cell size/mass when compared with age-
matched control mice.
Moreover,themaximallipolyticactivityoftheadipocytes
was elevated in the semicarbazide-treated group: in fat cells
isolated from epididymal plus retroperitoneal and perirenal
fat pads (pooled as visceral WAT, to obtain suﬃcient amount
of biological material for the various determinations), the
glycerol released in response to 10μM isoprenaline was 3.14
± 0.72 versus 1.90 ± 0.20μmol/100mg lipids/90min in
control (n = 4, P<. 05). Such observation supported that
these small adipocytes were more metabolically active than
larger fat cells. Therefore, chronic semicarbazide ingestion
clearly appeared to prevent adipocyte hypertrophy and to
facilitate lipid mobilization.
3.3. Benzylamine-Dependent Eﬀects in Adipocytes. Of worth
was to investigate whether the insulin-like eﬀects of aminesJournal of Obesity 5
were abolished in fat cells after SSAO blockade. The glucose
uptake was measured ex vivo in adipocytes isolated from
visceral WAT. The submaximal stimulation of deoxyglucose
uptake by 10nM insulin reached 2.9 ± 0.3-fold increase
over basal in control adipocytes, while it was equivalent
to a 4.5 ± 0.5-fold increase in semicarbazide-drinking
mice (n = 8, P<. 01). Again, the smaller fat cell
size of semicarbazide-treated mice likely accounted for
such enhanced insulin responsiveness. On the opposite, the
insulin-like eﬀect of benzylamine was dramatically impaired
in the semicarbazide-treated mice, especially when the SSAO
substrate was tested at 0.1mM in the presence of 0.1mM
vanadium (Figure 4). The combination of vanadium and
benzylamine produced more than 80% of the maximal
insulin eﬀect in control cells, as previously reported [16],
whereas this eﬀect did not exceed 25% after semicarbazide
treatment. Similarly, the weak eﬀect of benzylamine alone
on glucose uptake also exhibited a tendency to be reduced
in semicarbazide-treated mice (not shown).
3.4. Amine Oxidase Activities in Adipose Tissue. It was then
veriﬁed whether SSAO activity was really blocked in WAT
after semicarbazide treatment. As shown in Figure 5(a),
the oxidation of benzylamine was totally abolished in the
subcutaneous WAT of semicarbazide-drinking mice. This
was in agreement with the fact that, in control WAT,
benzylamine oxidation was exclusively SSAO-dependent. On
the contrary, tyramine was oxidized by SSAO and MAO
as well. Its oxidation was lower in the semicarbazide-
treated mice than in control. The remaining tyramine
oxidationfoundaftersemicarbazidetreatmentwasexplained
by an unaltered MAO-dependent oxidation together with
an almost total disappearance of the SSAO component
(Figure 5(b)). A similar obliteration of SSAO activity was
found in visceral WAT after semicarbazide treatment: the
oxidation of 0.1mM benzylamine fell from 2.74 ± 0.28 to
0.06 ± 0.02nmol/mgprotein/min (n = 6, P<. 001).
The total blockade of SSAO activity obtained after semi-
carbazide treatment was not accompanied by any alteration
of MAO activity. This was supported by the lack of change
in the expression of genes encoding for the monoamine
oxidases A and B in adipocytes (Table 2). Similarly, there
was no change for AOC2 gene, which is poorly expressed in
WAT. More surprising was the decline in AOC3 expression,
the gene encoding for SSAO, traducing that prolonged
semicarbazide treatment did not only inhibit the SSAO
enzymatic activity but also reduced its expression in WAT.
3.5. Semicarbazide-Induced Changes in Gene Expression in
Adipocytes. To further analyse the changes occurring in
adipose tissue after semicarbazide treatment, the expres-
sion of several genes was quantiﬁed in adipocytes from
visceral WAT. As expected, the leptin expression was strongly
inhibited in adipocytes from the smaller fat pads found
in the semicarbazide-treated group (Table 2). However, no
noticeable change in the expression of other adipokines was
found,irrespectiveoftheirdetrimental(TNFα,IL-6,resistin)
or beneﬁcial (adiponectin) eﬀect on insulin resistance, with
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Figure 4: Inﬂuence of 8-week oral administration of semicarbazide
on benzylamine-induced glucose transport in mouse adipocytes.
Visceral adipocytes were incubated with 0.1mM benzylamine alone
(bza) or combined with 0.1mM vanadate (bza + van) for 2-
DG uptake assay. Data are expressed as percentage of response to
100nM insulin, which maximally stimulated basal uptake by 3.3
± 0.4-fold in control (black columns) and by 4.8 ± 0.8-fold in
semicarbazide-drinking mice (open columns). Mean ± SEM of 8
determinations. Diﬀerent from control at ∗∗P<. 01.
the exception of apelin, the mRNA abundance of which
exhibited a 50% reduction that failed to reach statistical
signiﬁcance (P<. 1). Regarding the genes involved in energy
supply to adipocytes, there was no clear change in LPL or
FAS expression (Table 2). The expression of the ubiquitous
glucose transporter GLUT1 was reduced, but not that of
the insulin-sensitive GLUT4. Catalase expression remained
unaﬀected (not shown). Lastly, the expression of the adi-
pogenic markers aP2 and PPARγ2 genes was unchanged in
the semicarbazide-treated group (they were equivalent to
77% and 93% of the levels found in control, resp.) while a
tendency to decrease was found for the macrophage marker
F4/80 (not shown). Taken together, these last observations
arguedthattheincreasedDNAcontentpermassunitofWAT
was not due to an increased adipogenesis or to an inﬁltration
of immune cells but was rather the consequence of the
reduced size of the adipocytes: being of smaller mass, they
were in higher number per 100mg tissue than in control, the
WAT of which was constituted with larger fat cells.
3.6. Absence of Abnormalities in the Circulating Metabolic
Parameters of Semicarbazide-Drinking Mice. Regarding the
adverse eﬀects that might be provoked by semicarbazide
prolongedingestion,nochangewasfoundattheplasmalevel
for the circulating values of glucose, insulin, triglycerides,
free fatty acids, or cholesterol (not shown). Similarly, the
plasma markers of lipid peroxidation did not diﬀer between
control and semicarbazide-drinking mice (malonyldialde-
h ydeequivalentswere23.9±2.0and22.5 ±3.2,resp.,n = 8).6 Journal of Obesity
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Figure 5:Inﬂuenceof8-weekoraltreatmentwithsemicarbazideon
the benzylamine (a) and tyramine (b) oxidation in subcutaneous
WAT. Homogenates were preincubated for 15 minutes without
(totaloxidation,blackcolumns),with0.5mMpargyline(inorderto
determine pargyline-sensitive component as MAO, open columns),
or with 1mM semicarbazide (to determine the semicarbazide-
sensitive component as SSAO, shaded columns). Then, they were
incubated for 30 minutes in the presence of 0.1mM benzylamine
(a) or 0.5mM tyramine (b). Mean ± SEM of 6 determinations.
Diﬀerent from corresponding control at ∗∗P<. 01, ∗∗∗P<. 001.
4. Discussion
The present study highlights decrease in both body weight
gain and fattening as marked consequences of semicarbazide
subchronic ingestion. The total SSAO blockade found in
WAT, together with the decreased lipogenic eﬀect of ben-
zylamine, which can be considered as one representative of
the dietary amines reaching visceral fat during the digestion
process, led us to propose that pharmacological inhibition of
SSAO can be considered as a way to mitigate obesity. Since
SSAO is largely expressed in fat depots, a peripheral mode
of action can be envisaged, but other central mechanisms,
Table 2: Gene expression in visceral adipocytes from semi-
carbazide-drinking or control mice.
Gene Control Semicarbazide-treated
Amine oxidases:
MAO-A 66.2 ± 22.3 35.9 ± 11.7
MAO-B 154 ± 21 133 ± 31
AOC2 2.0 ± 0.4 1.5 ± 0.2
AOC3 4750 ± 555 2420 ± 275∗∗
Adipokines:
Adiponectin 22568 ± 1942 19068 ± 2195
Resistin 3837 ± 300 4143 ± 374
leptin 2068 ± 365 853 ± 80∗∗
IL-6 792 ± 230 718 ± 198
TNF-alpha 16.9 ± 2.6 23.5 ± 8.1
Apelin 26.0 ± 9.3 12.5 ± 4.3
Fuel metabolism:
GLUT1 187 ± 28 103 ± 18∗
GLUT4 440 ± 38 429 ± 51
LPL 47742 ± 3860 39274 ± 3152
mRNA abundance of the indicated genes was determined by rt-PCR and
expressed using the arbitrary units detailed in Section 2.M e a n± SEM of 8
determinations. Diﬀerent from control at ∗P<. 05; ∗∗P<. 01.
participating to the observed 12% reduction of calorie intake
cannot be excluded.
The clear-cut blockade of benzylamine oxidation found
in the WAT of treated mice agrees with the fact that
benzylamine oxidation is almost exclusively catalyzed by
SSAO activity in this tissue. As a consequence, the insulin-
like action of the SSAO substrate benzylamine on glucose
transport was abolished in adipocytes from semicarbazide-
treated mice. This was concomitant with substantial reduc-
tions in the fat mass and in the mean fat cell size. Whether
thedecreaseinSSAOexpression wasaconsequenceoffatcell
size reduction appears unlikely since the shrinking of lipid
stores observed during prolonged fasting is not accompanied
by a reduction of SSAO activity in adipose depots [28].
On the opposite, agents known to inhibit SSAO have been
observed to limit lipogenesis in vitro [20]. On the basis
of these previous observations, it can be proposed that
inhibition of lipogenic eﬀects of endogenous/dietary SSAO
substrates participates to the limitation of fat deposition.
The reduced number of large adipocytes together with the
increased DNA content per WAT mass and the unchanged
adipocyte diﬀerentiation markers (aP2, PPARγ2), indicated
that the diﬀerentiated adipocytes already present at the
beginning of treatment, at the age of 5 weeks, were less
capable to accumulate lipids in semicarbazide-drinking
mice than in the control group. The resulting fat cells of
moderate size were present in a larger number per mass
unit and consequently gave higher DNA richness per mass
unit of WAT, higher lipolytic capacity, and higher insulin
responsiveness. In this view, the inhibition of peripheral
SSAO, which is abundant in fat cells [15, 25], but which is
not expressed in neurones, may represent a fascinating novelJournal of Obesity 7
approach to modulate WAT development. Such paradigm is
relevant only whether endogenous or dietary amines spon-
taneously exert insulin-like eﬀects, which is far from being
demonstrated. Indeed, it is widely accepted that numerous
amines are spontaneously present in foods [30, 31]o r
may be generated during digestion process by the intestinal
ﬂora [32]: for instance, tyramine is present at around
45mg/kg in rodent chow [33] and benzylamine reaches
around 3–10mg/kg in edible vegetables [34]. However, it
has never been demonstrated (or ruled out) whether such
dietary amines might exert in vivo the lipogenic eﬀects they
exhibit in vitro [19], and so facilitate fat accretion once
ingested.
Moreover, SSAO is not only expressed in fat cells but
also in vessels, in endothelial cells, where it is involved
in leukocyte extravasation, and in smooth muscle cells,
where it is involved in glucose transport [11] and in
collagen-elastin maturation [2, 3]. The tendency to decrease
the F4/80 macrophage marker level found in mice after
semicarbazide exposure is probably related to the anti-
inﬂammatory properties of SSAO/VAP-1 blocking agents
[35]. Whether the improved in vitro responsiveness to
insulin in the adipocytes from semicarbazide-drinking mice
is a consequence of such reduced low-grade inﬂammation
or is related to the smaller size of fat cells remains to
be determined. In the treated adipocytes, there was no
change in the expression of TNFα and IL-6, two cytokines
involved in insulin resistance, together with a decrease of
the proinﬂammatory adipokine leptin and a tendency to
lower the expression of apelin, another adipokine recently
shown to facilitate glucose utilization [36]. Such absence
of enhanced WAT inﬂammation was associated with an
absence of oxidative stress (evidenced by unchanged lipid
peroxidation markers or catalase content). This context
may explain the increased ex vivo insulin responsiveness
of adipocytes, which was not suﬃcient to ﬁll the fat
cells of semicarbazide-drinking mice via sustained lipogenic
pathways, since it was occurring together with a reduced
calorie intake. Of interest is to test whether the insulin-
sensitizing action of SSAO blockade also occurs acutely in
obese insulin-resistant models, and improve the insulin-
dependent and independent antilipolytic responses, since
adipose tissue lipolysis regulation has been proposed to
be instrumental in the treatment of obesity and metabolic
syndrome [37].
The major concern is that semicarbazide itself cannot
currently be proposed as antiobesity drug since this deriva-
tive has been described to exert deleterious toxic eﬀects. In
2003, the European Food Safety Authority has banned the
use of azodicarbonamide as a blowing agent for plastics used
infoodprocessingorpackaging,orasaﬂourtreatment,since
it can be transformed into semicarbazide, which is suspected
to be a food contaminant exerting toxicological eﬀects on
consumers. However, this hydrazine derivative is not only
a food contaminant, the origin of which is limited to the
transformation of known chemical substances used (or even
prohibited) in food processing [23], but can also naturally
occur in certain foods [38, 39]. As a consequence, the
DNA damaging eﬀects of ingested semicarbazide have been
intensivelystudiedtobringhealthriskassessments.Butthese
recent toxicological studies inconsistently demonstrated the
genotoxic properties of semicarbazide, since they raised vari-
ations according to the model and the protocol used. Brieﬂy,
semicarbazide has very poor genotoxic eﬀects on human
lymphocytes when tested in vitro [23] and is not genotoxic
in mice when administered in vivo at 120mg/kgb.w. [29].
However semicarbazide exhibits carcinogenic potential—
withmarginal statistical relevance—whenorallygiven to rats
at 150mg/kg [23]. Of note, other aspects of semicarbazide
toxicity have also been stated very recently and have pro-
duced more consensual results. Indeed, a toxicological study
showed a dramatic decrease in body weight with orally given
semicarbazide as mixed in the food at doses up to 1000ppm,
givingadailyintakeof65to70mg/kginmaleandfemalerats
[22]. The decrease in adiposity was not assessed in this study.
However, the relative weights of the brain, heart, and kidneys
were unchanged or even increased, depending on the sex,
while body weights were clearly lower in the semicarbazide-
treated rats. This may indicate that while semicarbazide
ingestion limits WAT expansion, as assessed in our condi-
tions,otherorgansarepreservedduringthebodyweightloss.
Unfortunately, exposure to semicarbazide was accompanied
by serious adverse eﬀects such as deformation of bones and
lesions of articular cartilages [22]. In the aorta, alteration
of connective tissues was suspected to increase fragility of
arterial walls. Nonetheless, no inﬂammatory disease was
found. In view of these toxicological eﬀects of chronic
exposure to semicarbazide, the no observed adverse eﬀect
level (NOAEL) was estimated by the authors to be lower than
18–21mg/kg/day in rat. Accordingly, the NOAEL in juvenile
rats on another strain has recently been proposed to be
lower than 40mg/kg for semicarbazide oral administration
[21]. In this study describing the toxicity of semicarbazide
on biochemical and behavioural parameters, the authors
observed a clear-cut inhibition of body weight gain and
defects in cartilage mineralization [21]. During the comple-
tionofthepresentwork,thesameitaliangroupreportedthat
semicarbazide behaves as an endocrine disrupter, being able
to reduce estrogen levels or to alter testosterone catabolism
[40]. Anyhow, semicarbazide inhibited body weight gain
and food consumption in postweaning male and female rats
whenorallygiven fromthe dose of 40 to 140mg/kg/d period.
Thus, semicarbazide administration is univocally rec-
ognized to reduce body weight gain in diverse obese or
nonobesemodels[2,3,7,8,21]andregardingthisaspectour
ﬁndings are conﬁrmatory. Our detailed analysis of adiposity
of juvenile mice, together with the high expression of SSAO
in adipocytes, brings novel insight, focusing the attention
on WAT as a major target of semicarbazide. However, this
hydrazine derivative cannot be safely used as a “slimming”
agent for toxic issues in bones, joints, and vessels. Although
other SSAO inhibitors have also been reported to limit
body weight gain, several semicarbazide eﬀects other than
inhibitingSSAOwillbediscussedhereinanattempttodetect
whetherSSAOblockadeisnecessaryand/orsuﬃcienttolimit
fat deposition.
Another well-recognized eﬀect of semicarbazide is to
inhibit lysyl oxidase, a copper-containing amine oxidase8 Journal of Obesity
involved in the stabilization of extracellular matrix by cross-
linking of proteins such as collagen and elastin [2, 3],
therefore explaining part of the semicarbazide toxic eﬀects
on bones and joints. However, the lysyl oxidase inhibitor
β-aminopropionitrile, reported to decrease insoluble elastin
and collagen content and to impair collagen cross-linking
does not decrease body weight gain, excepted when com-
bined with semicarbazide [3].
Semicarbazide has been reported to inhibit glutamic acid
decarboxylase, a γ-amino butyric acid-synthesizing enzyme
[41, 42], and its administration is therefore believed to
impairγ-aminobutyricacid(GABA)formationandtolower
GABAbrainlevels.Thishasbeenproventoinduce“freezing”
behaviour in rodents after central administration [43]. How-
ever,itisstrikingtonotethatrelativelyhighdosesofgamma-
vinyl GABA, an irreversible inhibitor of the enzyme GABA-
transaminase, which is involved GABA catabolic pathway,
have been recently reported to produce signiﬁcant weight
loss in rats [44]. Likewise, another inhibitor of the GABA
degradation exhibits anorectic potency in obese rats [45],
while it has been proposed that a rat strain resistant to high-
fat diet feeding reduces its food intake via an elevation of
brain GABA levels [46]. In fact, it is diﬃcult to understand
how the chronic in vivo administration of semicarbazide,
supposed to inhibit GABA synthesis, alters the GABA-ergic
systems in a manner that results in reduced food intake,
as it is the case with inhibitors of GABA degradation. To
pour more complexity, it has been recently reported that
several semicarbazide derivatives elevate GABA levels in the
midbrain and exert anticonvulsant activity [47]. It could be
therefore of interest to determine the relative proportion
of the central GABA-ergic alterations and of the peripheral
SSAO blockade in the “slimming” action of semicarbazide
before establishing whether more selective SSAO blockers,
devoid of interaction with the GABA-ergic system, also elicit
antiobesity eﬀects. Otherwise, the current number of SSAO-
interacting agents that have been also reported to reduce
weight gain (FPFA [1], aminoguanidine [6], phenelzine [8])
suggests a nonnegligible inﬂuence of the component related
to SSAO inhibition in the observed eﬀect of semicarbazide.
Semicarbazide has also been described to inhibit
sphingosine-1-phosphate (S1P) lyase [48] ,b u ti ti sn o t
clear whether such nonspeciﬁc inhibition may have some
bearing on our observations. As in the case of GABA-
ergic system, it must be quoted that novel semicarbazide
derivatives act diﬀerently from semicarbazide itself, since
instead of inhibiting a S1P-degrading enzyme, they are
selective inhibitors of a subset of the G protein-coupled S1P
receptors (S1P2) [49]. This emphasizes that semicarbazide is
a molecule with multiple aspects, each one being selectively
developed by the association of a functional and selective
moiety to the semicarbazide turntable structure. Such drug
design is out of the scope of the present study, while
SSAO inhibition, obtained by the various above-mentioned
pharmacological agents was always found to be concomitant
with a decreased body weight gain. The need for searching
novel, selective SSAO inhibitors is not only a concern for
our proposed antiobesity pharmacology, but also relies with
the general biology of the enzyme, which will soon change
of denomination, from SSAO to primary amine oxidase, a
fact indicating that its deﬁnition based on its sensitivity to
semicarbazide will become historical once the many other
inhibitors under development will be fully characterized.
5. Conclusions
Taken together, our results demonstrate that oral admin-
istration of the prototypical SSAO inhibitor semicarbazide
limits weight gain and fat deposition in mouse. In spite of
the toxicity of the high doses of this agent, the use of other
speciﬁc SSAO inhibitors might reveal more beneﬁcial for the
pharmacologic treatment of obesity.
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